Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: STAA

STAAR Surgical Company

Healthcare | Medical - Instruments & Supplies

No licensed closing price on file for STAA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2026)$-1.62

STAAR Surgical Company (NASDAQ: STAA) is a medical instruments and supplies company. Figures from SEC EDGAR; updated 2026-10-19 21:58 UTC.

What STAAR Surgical Company does

STAAR Surgical designs, manufactures, and sells implantable lenses called ICLs made from a proprietary material called Collamer that are implanted in the eye to correct vision problems without removing the eye's natural lens. The company generates nearly all its revenue from ICL sales, offering products to treat nearsightedness, farsightedness, and astigmatism, with some newer products addressing age-related focusing issues.

Summarized from STAAR Surgical Company’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2026)$-1.62

Revenue, margins & earnings

FY2022 Net income: $40MFY2022 Taxes & interest: $4MFY2022 Operating expenses: $180MFY2022 Cost of revenue: $16M$239MFY2022FY2023 Net income: $21MFY2023 Taxes & interest: $7MFY2023 Operating expenses: $225MFY2023 Cost of revenue: $70M$322MFY2023FY2024: net loss $20M on revenue $314M$314MFY2024FY2025: net loss $80M on revenue $239M$239MFY2025FY2026: net loss $80M on revenue $239M$239MFY2026
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-18
  • 2026-08-18President and CEOPerformance Stock UnitsOption exercise3,666—
  • 2026-08-18President and CEOPerformance Stock Option (right to buy)Award131,830—
  • 2026-08-18President and CEOPerformance Stock UnitsOption exercise7,331—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does STAAR Surgical Company do?

STAAR Surgical designs, manufactures, and sells implantable lenses called ICLs made from a proprietary material called Collamer that are implanted in the eye to correct vision problems without removing the eye's natural lens.

When did STAA last file with the SEC?

STAAR Surgical Company's most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 21:58 UTC. This page is also available as JSON at /api/data?ticker=STAA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for STAA and 5,000+ tickers.

Create a free account — keep STAA
For your agent
GET /api/data?ticker=STAA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt